EUCTR2006-001947-70-SK进行中（未招募）1 期
A Double Blind, Placebo Controlled Multi-Center Pilot Study to Evaluate the Efficacy and Safety of MBP8298 in Relapsing Remitting Multiple Sclerosis
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 215
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female subjects, 18-50 years of age
- •2. Relapsing-remitting multiple sclerosis (RRMS) according to Diagnostic criteria for multiple sclerosis: 2005 revisions to the McDonald Criteria” (Annals of Neurology 58: 840-846)
- •3. At least 2 years history of MS before trial entry
- •4. Documented history of 2 or more exacerbations in the 2 years prior to trial entry
- •5. Stable neurological status for at least 30 days before first study drug administration
- •6. Have an EDSS from 0-5.5
- •7. If female, she must either
- •- be post-menopausal or surgically sterilized; or
- •- use a hormonal contraceptive, intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study; and
- •- be neither pregnant nor breast-feeding
- •8. Willingness and ability to comply with the protocol for the duration of the study
- •9. In the Investigator’s opinion, subjects must be reliable, compliant, and agree to cooperate with all trial evaluations
- •10. Subject must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with regulatory requirements
- •Are the trial subjects under 18?
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years)
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Have Clinically Isolated Syndrome (CIS), Secondary Progressive MS (SPMS), Primary Progressive MS (PPMS)
- •2. Any known malignancy, or history of malignancy, with the exclusion of basal cell carcinoma
- •3. Have active, clinically significant liver, renal or bone marrow disease accompanied with significant laboratory abnormalities in the range of grade I or more as defined by Common Toxicity Criteria (CTC),
- •4. Clinically significant ECG abnormalities at screening
- •5. Have the presence of systemic disease that, in the opinion of the investigator, might interfere with subject safety, compliance or evaluation of the condition under study (e.g. insulin dependent diabetes, lyme disease, clinically significant cardiac, hepatic, or renal disease, Human Immunodeficiency Virus, or Human T-Cell Lymphotrophic Virus Type-1)
- •6. Have current autoimmune disease, compromised immune function or infection
- •7. History of allergic reactions to glatiramer acetate
- •8. Steroid therapy within 30 days prior to first study specific procedure, or any other treatment known to be used for putative or experimental MS treatment
- •9. Therapy with ß-interferon, glatiramer acetate, statins, copaxone or nonspecific phosphodiesterase inhibitors within 3 months prior to first study-specific test
- •10. Therapy with mitoxantrone, cyclophosphamide, methotrexate, azathioprine, or any other immuno-modulating (e.g. IVIG) or immunosuppressive drugs including recombinant or non-recombinant cytokines or plasma exchange within 6 months prior to performance of the first study-specific test, with the exception of corticosteroids or ACTH for relapse treatment
- •11. Treatment at any time with an altered peptide ligand, cladribine, total lymphoid irradiation, monoclonal anti-body treatment e.g. anti-CD4, anti-CD52, anti-VLA4, Anti-CD20,
- •12. Any contraindications for MRI, e.g. pacemaker or known allergy to Gadolinium-DTPA
- •13. Participation in any other trial of an investigational agent within 90 days prior to screening
- •14. History of alcohol or drug abuse as specified by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) within the year before screening
- •15. Any medical, psychiatric or other condition that could result in a subject not being able to give fully informed consent, or to comply with the protocol requirements
- •16. Any other condition that, in the Investigator’s opinion, makes the subject unsuitable for participation in the study
研究者
相似试验
进行中（未招募）
不适用
A double blind, placebo-controlled, multi-centre study to evaluate the efficacy, safety, tolerability and immunogenicity of repeated s.c administrations of 100µg NIC002 vaccine in cigarette smokers who are motivated to quit smokingSmokersEUCTR2007-006741-40-DEovartis Pharma Services AG200
进行中（未招募）
不适用
A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Standard of Care.-----------------------------------------------------------------------------------------------Estudio multicéntrico, doble ciego, controlado con placebo y aleatorizado de TroVax? frente a placebo en el tratamiento de primera línea de pacientes con cáncer colorrectal metastásico que reciben el tratamiento habitual. - FLAMENCOMetastatic Colorectal Adenocarcinoma.-----------------------------------------------Adenocarcinoma Colorectal Metastásico.MedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2007-005639-26-ESOxford BioMedica1,300
进行中（未招募）
不适用
A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Chemo-based Therapy. - FLAMENCOMetastatic Colorectal AdenocarcinomaMedDRA version: 9.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerEUCTR2007-005639-26-DEOxford BioMedica (UK) Limited1,312
进行中（未招募）
1 期
A Multicenter, Double Blind, Placebo controlled, Randomized study of TroVax vs Placebo in the First Line treatment of Patients with Metastatic Colorectal Cancer receiving Chemo-based Therapy. - FLAMENCOMetastatic Colorectal AdenocarcinomaMedDRA version: 9.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancerEUCTR2007-005639-26-GBOxford BioMedica1,312
进行中（未招募）
1 期
A Multicenter, Double-Blind, Randomized, Placebo and Active Comparator Controlled Dose Range Finding Study in MK-0893 in Patients with Type 2 Diabetes Mellitus Who Have Indequate Glycemic Control. - A dose-range finding study for MK-0893MedDRA version: 9.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitusType 2 Diabetes MellitusEUCTR2007-001691-36-HUMerck & Co., Inc.750